Ostéoporose et médecine personnalisée

J. Y. Reginster, A. Neuprez, M. P. Lecart, C. Beaudart, F. Buckinx, J. Slomian, O. Bruyère

Résultats de recherche: Contribution à un journal/une revueArticleRevue par des pairs

2 Téléchargements (Pure)

Résumé

Osteoporosis is at the very early stages of the implementation of personalized medicine. However, the development of FRAX®, an algorithm offering the opportunity to calculate, in an individual patient, his/her 10-year fracture risk improves the decision process on the appropriateness to initiate a pharmacological treatment. This algorithm helps the physician to select drugs which are active on non-vertebral fractures only in high risk patients. Taking into consideration patients' preferences, when selecting a therapeutic option, will improve long term adherence and subsequently efficacy and efficiency of the treatments. Attempts to define the natural course of osteoporosis or the response to therapy in individual patients by assessing their genetic profile remains, so far, inconclusive.

Titre traduit de la contributionOsteoporosis and personalized medicine
langue originaleFrançais
Pages (de - à)321-324
Nombre de pages4
journalRevue Medicale de Liege
Volume70
Numéro de publication5-6
Etat de la publicationPublié - 2015
Modification externeOui

mots-clés

  • Adherence
  • FRAX®
  • Osteoporosis
  • Personalized medicine
  • Treatment

Empreinte digitale

Examiner les sujets de recherche de « Ostéoporose et médecine personnalisée ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation